Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.

<h4>Background and objectives</h4>Five-tumour necrosis factor (TNF)-blockers (infliximab, etanercept, adalimumab, certolizumab pegol and golimumab) are available for treatment of rheumatoid arthritis. Only few clinical trials compare one TNF-blocker to another. Hence, a systematic review...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kalle J Aaltonen, Liisa M Virkki, Antti Malmivaara, Yrjö T Konttinen, Dan C Nordström, Marja Blom
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b4c22d51390b49cba7d9ffc31379170a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b4c22d51390b49cba7d9ffc31379170a
record_format	dspace
spelling	oai:doaj.org-article:b4c22d51390b49cba7d9ffc31379170a2021-11-18T07:30:06ZSystematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.1932-620310.1371/journal.pone.0030275https://doaj.org/article/b4c22d51390b49cba7d9ffc31379170a2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22272322/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background and objectives</h4>Five-tumour necrosis factor (TNF)-blockers (infliximab, etanercept, adalimumab, certolizumab pegol and golimumab) are available for treatment of rheumatoid arthritis. Only few clinical trials compare one TNF-blocker to another. Hence, a systematic review is required to indirectly compare the substances. The aim of our study is to estimate the efficacy and the safety of TNF-blockers in the treatment of rheumatoid arthritis (RA) and indirectly compare all five currently available blockers by combining the results from included randomized clinical trials (RCT).<h4>Methods</h4>A systematic literature review was conducted using databases including: MEDLINE, SCOPUS (including EMBASE), Cochrane library and electronic search alerts. Only articles reporting double-blind RCTs of TNF-blockers vs. placebo, with or without concomitant methotrexate (MTX), in treatment of RA were selected. Data collected were information of patients, interventions, controls, outcomes, study methods and eventual sources of bias.<h4>Results</h4>Forty-one articles reporting on 26 RCTs were included in the systematic review and meta-analysis. Five RCTs studied infliximab, seven etanercept, eight adalimumab, three golimumab and three certolizumab. TNF-blockers were more efficacious than placebo at all time points but were comparable to MTX. TNF-blocker and MTX combination was superior to either MTX or TNF-blocker alone. Increasing doses did not improve the efficacy. TNF-blockers were relatively safe compared to either MTX or placebo.<h4>Conclusions</h4>No single substance clearly rose above others in efficacy, but the results of the safety analyses suggest that etanercept might be the safest alternative. Interestingly, MTX performs nearly identically considering both efficacy and safety aspects with a margin of costs.Kalle J AaltonenLiisa M VirkkiAntti MalmivaaraYrjö T KonttinenDan C NordströmMarja BlomPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 1, p e30275 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kalle J Aaltonen Liisa M Virkki Antti Malmivaara Yrjö T Konttinen Dan C Nordström Marja Blom Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
description	<h4>Background and objectives</h4>Five-tumour necrosis factor (TNF)-blockers (infliximab, etanercept, adalimumab, certolizumab pegol and golimumab) are available for treatment of rheumatoid arthritis. Only few clinical trials compare one TNF-blocker to another. Hence, a systematic review is required to indirectly compare the substances. The aim of our study is to estimate the efficacy and the safety of TNF-blockers in the treatment of rheumatoid arthritis (RA) and indirectly compare all five currently available blockers by combining the results from included randomized clinical trials (RCT).<h4>Methods</h4>A systematic literature review was conducted using databases including: MEDLINE, SCOPUS (including EMBASE), Cochrane library and electronic search alerts. Only articles reporting double-blind RCTs of TNF-blockers vs. placebo, with or without concomitant methotrexate (MTX), in treatment of RA were selected. Data collected were information of patients, interventions, controls, outcomes, study methods and eventual sources of bias.<h4>Results</h4>Forty-one articles reporting on 26 RCTs were included in the systematic review and meta-analysis. Five RCTs studied infliximab, seven etanercept, eight adalimumab, three golimumab and three certolizumab. TNF-blockers were more efficacious than placebo at all time points but were comparable to MTX. TNF-blocker and MTX combination was superior to either MTX or TNF-blocker alone. Increasing doses did not improve the efficacy. TNF-blockers were relatively safe compared to either MTX or placebo.<h4>Conclusions</h4>No single substance clearly rose above others in efficacy, but the results of the safety analyses suggest that etanercept might be the safest alternative. Interestingly, MTX performs nearly identically considering both efficacy and safety aspects with a margin of costs.
format	article
author	Kalle J Aaltonen Liisa M Virkki Antti Malmivaara Yrjö T Konttinen Dan C Nordström Marja Blom
author_facet	Kalle J Aaltonen Liisa M Virkki Antti Malmivaara Yrjö T Konttinen Dan C Nordström Marja Blom
author_sort	Kalle J Aaltonen
title	Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
title_short	Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
title_full	Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
title_fullStr	Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
title_full_unstemmed	Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
title_sort	systematic review and meta-analysis of the efficacy and safety of existing tnf blocking agents in treatment of rheumatoid arthritis.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/b4c22d51390b49cba7d9ffc31379170a
work_keys_str_mv	AT kallejaaltonen systematicreviewandmetaanalysisoftheefficacyandsafetyofexistingtnfblockingagentsintreatmentofrheumatoidarthritis AT liisamvirkki systematicreviewandmetaanalysisoftheefficacyandsafetyofexistingtnfblockingagentsintreatmentofrheumatoidarthritis AT anttimalmivaara systematicreviewandmetaanalysisoftheefficacyandsafetyofexistingtnfblockingagentsintreatmentofrheumatoidarthritis AT yrjotkonttinen systematicreviewandmetaanalysisoftheefficacyandsafetyofexistingtnfblockingagentsintreatmentofrheumatoidarthritis AT dancnordstrom systematicreviewandmetaanalysisoftheefficacyandsafetyofexistingtnfblockingagentsintreatmentofrheumatoidarthritis AT marjablom systematicreviewandmetaanalysisoftheefficacyandsafetyofexistingtnfblockingagentsintreatmentofrheumatoidarthritis
_version_	1718423370341548032

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.

Ejemplares similares